- Datum14.08.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
XTB
NYKODE THERAP. NK -,05 Chart

Charts analysieren
wie die Profis?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse und handle direkt aus dem Chart bei Deinem Broker.
Chart analysieren
NYKODE THERAP. NK -,05 Realtime-Kurs
Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Stuttgart | VK | |||||
Baader | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (L&S)
Passender Service zu NYKODE THERAP. NK -,05
Webinar zu NYKODE THERAP. NK -,05
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)---
- Jahrestief / Hoch (€)0,098-0,237
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von NYKODE THERAP. NK -,05
Termine von NYKODE THERAP. NK -,05
- Aug20NYKODE THERAP. NK -,05Q2 2025 Earnings Release
- Nov26NYKODE THERAP. NK -,05Q3 2025 Earnings Release
- Feb25NYKODE THERAP. NK -,05Q4 2025 Earnings Release
Beschreibung
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.